...
首页> 外文期刊>Cancer Management and Research >Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway
【24h】

Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway

机译:非编码RNA NEAT1 / miR-214-3p通过Wnt /β-catenin途径初步促进尿路上皮膀胱癌的阿霉素抗性

获取原文

摘要

Background: Urothelial bladder cancer (UBC) is one of the most lethal urological malignancies in the world. Patients with UBC are routinely given chemotherapy which results in a median survival of 12-15 months. Nuclear-enriched abundant transcript 1 (NEAT1) functions as an oncogene and could be used as a therapeutic target for human UBC. However, the involvement of NEAT1 in doxorubicin (DOX) resistance of UBC has been poorly demonstrated. Methods: Quantitative Real-time PCR (qRT-PCR) was used to detect the expression levels of NEAT1 and miR-214-3p in UBC tissues and cells. Bioinformatics prediction, RNA pull-down and qRT-PCR were used to assay the regulation manner of NEAT1 and miR-214-3p. Loss/gain function of NEAT1 and miR-214-3p together with western blot, drug resistance assay and flow cytometry were used to explore the influence of NEAT1 in DOX resistance was correlative with miR-214-3p. Finally, luciferase assay system was applied to determine the Wnt/β-catenin signal activity. Results: NEAT1 was upregulated and miR-214-3p was downregulated in DOX-resistant UBC tissues and cells. NEAT1 knockdown inhibited J82 and T24 cells to DOX chemosensitivity by negatively regulating miR-214-3p expression. NEAT1/miR-214-3p contributed to DOX resistance of UBC preliminary through the Wnt/β-catenin pathway. Conclusion: NEAT1 contributed to DOX resistance of UBC through the Wnt/β-catenin pathway partly by negatively regulating miR-214-3p expression. Our findings will provide a promising ncRNA targeted therapeutic strategy for UBC with DOX resistance.
机译:背景:膀胱膀胱癌(UBC)是世界上最致命的泌尿外科恶性肿瘤之一。患有UBC的患者常规接受化学疗法,其平均生存期为12-15个月。富核丰富的转录本1(NEAT1)充当癌基因,可以用作人类UBC的治疗靶标。但是,NEAT1参与UBC对阿霉素(DOX)的耐药性的研究很少。方法:采用实时荧光定量PCR(qRT-PCR)检测UBC组织和细胞中NEAT1和miR-214-3p的表达水平。利用生物信息学预测,RNA下拉和qRT-PCR来检测NEAT1和miR-214-3p的调控方式。利用NEAT1和miR-214-3p的缺失/获得功能,结合蛋白印迹,耐药性分析和流式细胞术,探讨了NEAT1对与miR-214-3p相关的DOX耐药性的影响。最后,应用萤光素酶测定系统测定Wnt /β-catenin信号活性。结果:耐DOX的UBC组织和细胞中NEAT1上调,而miR-214-3p下调。 NEAT1组合式通过负调节miR-214-3p表达来抑制J82和T24细胞对DOX的化学敏感性。 NEAT1 / miR-214-3p通过Wnt /β-catenin途径初步促进了UBC的DOX抗性。结论:NEAT1部分通过负调控miR-214-3p表达,通过Wnt /β-catenin途径促进UBC对DOX的抗性。我们的发现将为具有DOX耐药性的UBC提供有希望的ncRNA靶向治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号